Clinical Trials in La Serena, Chile

7 recruiting

Showing 120 of 20 trials

Recruiting
Phase 3

A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

Metastatic Castration-resistant Prostate Cancer
Pfizer900 enrolled240 locationsNCT06629779
Recruiting
Phase 2Phase 3

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

Diffuse Large B Cell LymphomaDLBCL
Merck Sharp & Dohme LLC290 enrolled132 locationsNCT05139017
Recruiting
Phase 3

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

Diffuse Large B Cell Lymphoma
Merck Sharp & Dohme LLC1,046 enrolled263 locationsNCT06717347
Recruiting
Phase 3

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

Triple Negative Breast Neoplasms
Merck Sharp & Dohme LLC1,000 enrolled261 locationsNCT06841354
Recruiting
Phase 3

Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)

Essential Thrombocythemia
Merck Sharp & Dohme LLC300 enrolled171 locationsNCT06456346
Recruiting
Phase 3

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

Cervical Cancer
Merck Sharp & Dohme LLC1,023 enrolled130 locationsNCT07216703
Recruiting
Phase 3

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

Solid TumorsHematologic Malignancies
Merck Sharp & Dohme LLC3,500 enrolled782 locationsNCT03486873
Recruiting
Phase 3

LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

Metabolic Dysfunction-Associated Steatohepatitis
Boehringer Ingelheim1,590 enrolled447 locationsNCT06632457
Recruiting
Phase 3

LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

Metabolic dysfunction-associated steatohepatitis (MASH)Liver Fibrosis
Boehringer Ingelheim1,800 enrolled526 locationsNCT06632444
Recruiting
Phase 3

A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH

MASH - Metabolic Dysfunction-Associated SteatohepatitisNASH - Nonalcoholic Steatohepatitis
Akero Therapeutics, Inc2,150 enrolled322 locationsNCT06528314
Recruiting
Phase 3

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

Breast Cancer (Early Breast Cancer)
AstraZeneca5,500 enrolled794 locationsNCT05952557
Recruiting
Phase 3

Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis

Primary Biliary Cholangitis
Gilead Sciences318 enrolled199 locationsNCT06051617
Recruiting
Phase 3

A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).

CLLLeukemia, Lymphocytic, Chronic, B-CellLymphoma, Small Lymphocytic+3 more
Merck Sharp & Dohme LLC735 enrolled54 locationsNCT05947851
Recruiting
Phase 3

A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

Myelodysplastic Syndromes
Takeda225 enrolled179 locationsNCT06499285
Recruiting
Phase 3

A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy

Breast Cancer (Early Breast Cancer)
AstraZeneca4,300 enrolled711 locationsNCT05774951
Recruiting
Phase 3

Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

Prostate Cancer Metastatic
Merck Sharp & Dohme LLC1,310 enrolled282 locationsNCT06136624
Recruiting
Phase 2

A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

Urothelial Carcinoma
Seagen, a wholly owned subsidiary of Pfizer372 enrolled223 locationsNCT04879329
Recruiting
Phase 3

Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents

Metastatic Castration-Sensitive Prostate Cancer
AstraZeneca1,800 enrolled410 locationsNCT06120491
Recruiting
Phase 2

A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)

Recurrent or Metastatic Solid Tumors
Daiichi Sankyo520 enrolled119 locationsNCT06330064
Recruiting
Not Applicable

Window Prophylaxis for Pediatric Tuberculosis Prevention Trial

TuberculosisAdolescentChildren+3 more
Pontificia Universidad Catolica de Chile647 enrolled13 locationsNCT07086820